Scientific Advisors: Preeminent Scientific Braintrust
Our executive team and Board of Directors is supported by a Scientific Advisory Board comprised of foremost medical and scientific experts in the fields of oncology, hematology, and immunotherapy.
Jeffrey Weber, M.D., Ph.D. – Chief Scientific Advisor and Chair, Scientific Advisory Board
Dr. Weber is the deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, where his primary focus is treating patients with melanoma and other cutaneous malignancies. Through his distinguished career, he has helped to pioneer development of checkpoint blockade immunotherapy strategies in melanoma, led studies into targeted therapies in melanoma, advanced understanding of potential toxicities from emerging immunotherapies, and explored novel immune therapy concepts.
Monzr M Al Malki, M.D.
Dr. Monzr Al Malki is a hematologist in Duarte, CA and is affiliated with City of Hope’s Helford Clinical Research Hospital. He received his medical degree from Damascus University Faculty of Medicine and has been in practice 14 years. He also speaks multiple languages, including Arabic and Spanish. He specializes in hematologic oncology and myeloproliferative disorder hematology-oncology and is experienced in aplastic anemia, hematopoietic stem cell transplantation, acute myeloid leukemia, hodgkin’s lymphoma, and multiple myeloma.
Miguel-Angel Perales, M.D.
Dr. Perales is the Deputy Chief of the Adult Bone Marrow Transplantation Service and Director of the Adult Bone Marrow Transplant Fellowship Program at Memorial Sloan Kettering Cancer Center in New York, as well as an Associate Professor of Medicine at Weill Cornell Medical College. He is an internationally recognized leader in the field of hematopoietic stem cell transplantation, serving as a current member of the Board of Directors of Be the Match (National Marrow Donor Program – NMDP) and the American Society of Blood and Marrow Transplantation (ASBMT), where he serves as Secretary and member of the executive committee. He has also held leadership positions and been extensively involved in activities of the Center for International Blood and Marrow Transplant Research (CIBMTR) and Blood and Marrow Transplantation Clinical Trials Network (BMT CTN). His research focuses on clinical and translational investigations of immune-based therapies in patients with cancer. Dr. Perales received his medical degree from the Free University of Brussels and completed postdoctoral training at the Tufts Medical Center and Memorial Sloan Kettering Cancer Center.
Paul Richardson, M.D.
After comprehensive training and certification in internal medicine, hematology and medical oncology, as well as acquiring additional expertise in cancer pharmacology and transplant at Dana Farber Cancer Institute from 1994 onwards, Dr. Richardson joined the Division of Hematologic Oncology and the Jerome Lipper Multiple Myeloma Center in December 1999. He was appointed Clinical Director of the Myeloma Center in January 2001 and has since led several novel, biologically derived translational efforts in multiple myeloma under the overall direction and mentorship of Kenneth Anderson, MD. These have been focused on the clinical study of new drugs in the Phase 1, 2, and 3 settings as principal investigator and first author of derived manuscripts. Currently, Dr. Richardson is leading multiple efforts studying the use of combination therapies predominantly in relapsed and refractory myeloma, an area of primary interest to him. He also serves as a principal investigator and study chairman for several clinical trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease designed to target resistance and reduce toxicity.
Jonathan Schneck, M.D., Ph.D.
Dr. Schneck is a professor of pathology, medicine, and oncology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Dr. Schneck received his undergraduate degree from Yeshiva University. He earned his M.D., Ph.D. in immunology from the Albert Einstein College of Medicine. After completing his degrees, he trained in pediatrics at the Children’s Hospital National Medical Center in Washington, D.C. From there he worked on the medical staff of the National Institute of Allergy and Immunology at the NIH in Bethesda and completed his postdoctoral training at the Laboratory of Immunology. He joined the Johns Hopkins faculty in 1990 as a junior faculty member. His team pioneered the development of artificial white blood cells, called artificial antigen-presenting cells (aAPCs), which show promise in training animals’ immune systems to fight diseases such as cancer. Dr. Schneck was the principal investigator of a research project funded by a $10.3 million NIH grant—the largest basic immunology grants ever received by Johns Hopkins. His research focuses on T cell immunology.
Juan Varela, M.D., Ph.D.
Dr. Varela obtained his M.D., Ph.D. from Medical University of South Carolina in 2010. He completed his residency training in internal medicine at the Osler medical training program at the Johns Hopkins Hospital, followed by fellowship training in hematology at the Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. Dr. Varela’s clinical interests include novel immune therapies for hematological malignancies and bone marrow transplantation, treatments for leukemia, lymphoma and multiple myeloma. He is the principal investigator for numerous national clinical trials. Dr. Varela is passionate about providing support to his patient and their families and caregivers. His personal and professional philosophy is to treat the patient, not just the disease.